These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1282638)

  • 21. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.
    Wang J; An L; Chen S; Ouyang J; Zhou R; Chen B; Yang Y
    Acta Haematol; 2009; 121(4):223-6. PubMed ID: 19546524
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials.
    Bennett CL; Stinson TJ; Lane D; Amylon M; Land VJ; Laver JH
    Med Pediatr Oncol; 2000 Feb; 34(2):92-6. PubMed ID: 10657867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health care outcomes case study: Febrile neutropenia.
    Holdsworth MT; Duncan MH
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
    Esser M; Brunner H
    Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US.
    Stephens JM; Li X; Reiner M; Tzivelekis S
    J Med Econ; 2016; 19(5):537-47. PubMed ID: 26745764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The costs of treating febrile neutropenia in six U.K. Hospitals.
    Leese B
    Eur J Cancer; 1993; 29A Suppl 7():S15-8. PubMed ID: 7508725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study inclusion criteria and presentation of results in a meta-analysis of granulocyte colony-stimulating factor for prevention of febrile neutropenia.
    Lathia N; Isogai PK; Cheung MC; Mittmann N
    J Clin Oncol; 2010 Dec; 28(36):e762-3; author reply e764. PubMed ID: 21079143
    [No Abstract]   [Full Text] [Related]  

  • 33. Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.
    Lyman GH; Kuderer NM; Balducci L
    Curr Opin Oncol; 1998 Jul; 10(4):291-6. PubMed ID: 9702395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy.
    Cosler LE; Calhoun EA; Agboola O; Lyman GH
    Pharmacotherapy; 2004 Apr; 24(4):488-94. PubMed ID: 15098803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using filgrastim efficiently.
    Dranitsaris G
    Pharmacoeconomics; 1996 May; 9(5):466-8. PubMed ID: 10161379
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer.
    Bennett CL
    Crit Rev Oncol Hematol; 2003 Oct; 48(Suppl):S71-4. PubMed ID: 14563524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.
    Faulds D; Lewis NJ; Milne RJ
    Pharmacoeconomics; 1992 Apr; 1(4):231-49. PubMed ID: 10147015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay?
    Bessmertny O; Cairo MS
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):435-40. PubMed ID: 12794520
    [No Abstract]   [Full Text] [Related]  

  • 39. Neutropenia.
    Foster CW
    Medsurg Nurs; 2011; 20(5):262, 264. PubMed ID: 22165786
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of granulocyte growth factors in solid tumours.
    Diaz-Rubio E; Adrover E
    Eur J Cancer; 1994; 30A(1):120-2. PubMed ID: 7511398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.